SightfileU.S. market data from official filings

XENON PHARMACEUTICALS INC (XENE)

Name: XENON PHARMACEUTICALS INC (XENE) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001582313 · EDGAR filings · Updated 2026-06-08

XENON PHARMACEUTICALS INC (XENE) has reported institutional ownership of 103.7%, with 290 institutional managers holding positions valued at $5.80B per the latest 13F reporting period.

Institutional ownership

103.7%

Institutional managers

290

Reported 13F value

$5.80B

Insider activity

36 trans.

−$21.8M net selling

Latest updates

2026-06-08 — Insider transaction reported (Form 4)
2026-06-08 — Insider transaction reported (Form 4)
2026-06-05 — Notice of proposed sale filed (Form 144)
2026-06-05 — Notice of proposed sale filed (Form 144)
2026-06-03 — Insider transaction reported (Form 4)
2026-06-03 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, XENON PHARMACEUTICALS INC has 290 institutional holders and institutional ownership of 103.7%.

Insider activity

Insiders reported 36 transactions (0 buys, 23 sells) across 6 reporting insiders, with a net reported value of −$21.8M.

Related companies

ALKERMES PLC (ALKS) · CG ONCOLOGY INC (CGON) · CENTESSA PHARMACEUTICALS PLC (CNTA) · TELEFLEX INCORPORATED (TFX) · CELCUITY INC (CELC) · MSA SAFETY INC (MSA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-08.